OPN-7486 / Opna Bio - LARVOL DELTA

Opna Bio Launches with $38 Million Series A Financing to Advance Novel Oncology Discovery Program and Diversified Pipeline of Clinical and Preclinical Programs (Businesswire) - "Opna Bio...announced today that it has raised $38 million in a Series A financing, led by Longitude Capital and Northpond Ventures, with additional participation from Menlo Ventures. The proceeds will be used to develop novel fragile-X mental retardation protein (FMRP) inhibitors in oncology as well as a diverse portfolio of clinical and preclinical oncology programs acquired from Plexxikon Inc....As part of Opna’s formation, the company acquired a portfolio of small molecule oncology therapeutics from Plexxikon Inc. The clinical-stage assets include: OPN-2853 (formerly PLX2853), a potential best-in-class bromo and extra terminal (BET) domain inhibitor currently in a Phase 1/2 clinical trial in combination with ruxolitinib (Jakafi^®) for myelofibrosis, a rare myeloid cancer; OPN-7486 (formerly PLX7486), a colony-stimulating factor 1 (CSF1) receptor inhibitor expected to begin a Phase 2 study in 2023."

Financing • New P2 trial • Hematological Malignancies • Myelofibrosis • Myeloproliferative Neoplasm • Oncology

[VIRTUAL] Unique NTRK3 Fusion in a Spindle Cell Sarcoma (CAP 2021) - "There are sufficient clinical and preclinical data to indicate that NTRK fusions predict sensitivity to TRK inhibitors such as larotrectinib, entrectinib, belizatinib, and PLX7486. He had a poor response and subsequently died from pulmonary complications related to metastases to the lungs. The fusion partner MEF2A has not previously been reported and may be related to being refractory to therapy and the poor outcome."

Oncology • Sarcoma • Solid Tumor • Spindle Cell Sarcoma • ALK • ETV6 • MYO5A • NTRK • NTRK2 • NTRK3 • ROS1